ArticleMolecular medicine (Cambridge, Mass.)2024

Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy.

Ge Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.